-transparent.png){kind=logo}
The metabolism and biliary excretion of trimetrexate (TMTX), a lipid soluble antifolate, were examined using a recirculating isolated perfused rat liver system. Elimination of TMTX into perfusate was biphasic and dose-independent, with distribution and elimination half-lives of 2 and 13 min. Two metabolites, M1 and M2, both known to inhibit dihydrofolate reductase activity, were present in perfusate only in small concentrations. However, of the total TMTX dose, approximately 50% was excreted in bile as M1, and 20% as M2. Up to 75% of the total dose was accounted for as TMTX, M1, or M2 in perfusate and bile.
Related Publications
L K Webster, and
W P Tong, and
J J McCormack
December 1986,
Biochemical pharmacology,
L K Webster, and
W P Tong, and
J J McCormack
June 2001,
Journal of pharmaceutical sciences,
L K Webster, and
W P Tong, and
J J McCormack
January 1987,
Cancer chemotherapy and pharmacology,
L K Webster, and
W P Tong, and
J J McCormack
December 1991,
Xenobiotica; the fate of foreign compounds in biological systems,
L K Webster, and
W P Tong, and
J J McCormack
March 1962,
The American journal of physiology,
L K Webster, and
W P Tong, and
J J McCormack
December 2001,
International journal of oncology,
L K Webster, and
W P Tong, and
J J McCormack
October 1988,
Cancer research,
L K Webster, and
W P Tong, and
J J McCormack
December 1994,
Journal of gastroenterology,
L K Webster, and
W P Tong, and
J J McCormack
May 1988,
Archives of biochemistry and biophysics,
L K Webster, and
W P Tong, and
J J McCormack
November 1969,
The Journal of pharmacology and experimental therapeutics,
